Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
Status:
Active, not recruiting
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients
with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and
bevacizumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread.